Heiko Bruhn will be attending the 24th Annual Biotech in Europe Forum (#Sachs_BEF) taking place on the 25th – 26th September 2024 at the Mövenpick Hotel Basel.
Returning for its 24th Annual Edition, this global bio-pharma industry event will address the investment challenges of 2024, as well as partnering and alliance management, with a view towards 2025. Key figures will share their insights in panels covering the macroeconomic landscape and innovations in therapeutic sectors. The event draws early-stage, late-stage, and public companies, alongside investors, analysts, and pharmaceutical executives. Supported by Europe’s pharmaceutical and biotech leaders, it will be covered by regular media partners.
The programme will consist of:
Day 1 (Wednesday, 25th September)
- State of the Markets Panel
- Venture & Private Equity Roundtable
- Investing in NextGen Obesity Drugs Panel
- AI Transforming BioPharma Panel: Beyond the Hype
- Platform Technologies & Novel Therapeutics Panel: Diverse Business Models
- Neurological Disorders Panel: Rapid Advances with New Targets & Modalities
Day 2 (Thursday, 26th September)
- Latest Trends in Dealmaking for Bio-Pharma Panel
- Chinese Science & Innovation Panel: Driving Cross-Border Dealmaking
- Partnering in Oncology Panel: Meeting Both Sides Needs
- Immuno-Oncology Progress Panel • Early-Stage Ventures Panel: Picking Winners
- Rising Stars – Biotech Seed Companies Session
Main Networking Reception – 25th of September
Farewell Reception – 26th of September
In-Person Meetings – 25th – 26th of September
Virtual Meetings via Online Meeting System – 2nd – 4th of October
Confirmed Keynote Speakers Include:
- Gregory Rall, Deputy Head, Innovation & Technology, InvestHK
- Laura Lane, VP, Lilly Ventures – Europe Head External Innovation, Eli Lilly and Company
- Lukas Engelberger, State Councillor, Department of Public Health, Canton of Basel-Stadt
- Renée Aguiar-Lucander, CEO, Calliditas Therapeutics AB
Confirmed Speakers & Chairs Include:
- Alessandra Polara, Senior Director, Global BD, F. Hoffmann-La Roche AG
- Alex Blyth, CEO, LIfT BioSciences Ltd.
- Alfred Slanetz, Founder & CEO, Geneius Biotechnology
- Anders Bue Klein, Co-Founder & CEO, Ousia Pharma ApS
- Andreas Wallnoefer, Partner, Jeito Capital
- Antoine Boulanger, Principal, Forbion
- Antti Vuolanto, CEO, Herantis Pharma Plc
- Aram Mangasarian, CEO, TME Pharma
- Asun Monfort, Investment Advisor, HBM Partners AG
- Berthold Hinzen, Global Head BD&L Transactions Immunology, Novartis AG
- Carlos Buesa, Founder & CEO, Oryzon Genomics, S.A.
- Christoph Korpus, Director Global Business Development & Licensing Oncology, Merck KGaA, Darmstadt, Germany
- Cindy Daniel, Head of Unit – Life Sciences & Healthcare – Equity Investments, European Investment Fund
- Darren Ji, Co-Founder, Chairman & CEO, Elpiscience Biopharmaceuticals Co. Ltd.
- Dimitrios Weedon-Topalopoulos, Managing Director, OrbiMed Advisors LLC
- Dragan Grabulovski, Founder & CEO, Grabulovski Consulting Services GmbH
- Edward van Wezel, Managing Partner, BioGeneration Ventures
- Eric Halioua, President & CEO, PDC*line Pharma SA
- Esteban Pombo-Villar, CTO, TargImmune Therapeutics AG
- Federico Bolognani, Chief Medical Officer, IAMA Therapeutics S.r.l.
- François Thomas, Operating Partner, Quadrille Capital
- Frank Grams, Chief Commercial Officer, Partex N.V.
- Gregory Rall, Deputy Head, Innovation & Technology, InvestHK
- Hakan Goker, Managing Director, M Ventures
- Helen Chen, Global Sector Co-Head, Healthcare & Life Sciences | Greater China Managing Partner, L.E.K. Consulting
- Hubert Birner, Managing Partner, TVM Capital Life Science
- Hugh Nuthall, Executive Director, Search & Evaluation Neuroscience, Eli Lilly and Company
- Isabella Schidrich, Senior Managing Director, Listings EMEA, Nasdaq
- Jean-Jacques Mention, Chief Business Officer, OSE Immunotherapeutics
- Jeremy Griggs, Executive Director, Search & Evaluation, GSK
- Jesus Baena, BD&L Transactions Director, Novartis AG
- Joachim Vogt, Director Search & Evaluation International, AbbVie, Inc.
- Josua Jordi, Discovery Area Lead in Metabolism, F. Hoffmann-La Roche AG
- Katharina Kreymborg, SVP, Curie.Bio
- Keld Flintholm Jørgensen, SVP & CBO, H. Lundbeck A/S
- Kelly Curtin, Managing Director, Stifel
- Konstantin Petropoulos, CBO & Managing Director, Secarna Pharmaceuticals GmbH & Co. KG
- Kristian Tryggvason, Founder & CEO, Alder Therapeutics AB
- Laurent Jacqueroud, BD & Investment Director, Cumulus Oncology
- Louise S. Dalbøge, Chief Science Officer, Gubra A/S
- Lynn Durham, Founder & CEO, STALICLA SA
- Magne Stoknes, Principal, Novo Holdings A/S
- Marianne Uteng, Managing Director, Novartis Venture Fund
- Marie Schroeder, Vice President, Novo Holdings A/S
- Marina Udier, CEO, Nouscom AG
- Matthieu Coutet, Partner, Sofinnova Partners
- Michael Altorfer, CEO, Swiss Biotech Association
- Michael Hübner, Director Early Innovation Partnering, Johnson & Johnson Innovation LLC
- Neil Anderson, Head of Science2Medicine iNNvest, Novo Nordisk A/S
- Olav Zilian, Senior Financial Analyst, Pictet & Cie
- Parker Moss, EVP Corporate Development, Exscientia
- Patrick Schwab, Senior Director, AI & Machine Learning, GSK
- Paul Bravetti, CEO, Brenus Pharma
- Paul Hermant, Partner, Bird & Bird LLP
- Rainer Strohmenger, Managing Partner, Wellington Partners
- Renée Aguiar-Lucander, CEO, Calliditas Therapeutics AB
- Rianne Ellenbroek, Principal, BioGeneration Ventures
- Ricardo Pacheco, Strategic Partnering, BD& Director, Insilico Medicine
- Richard Ward, Executive Director, Search & Evaluation, AstraZeneca
- Rupert Haynes, CEO, Avata Biosciences
- Sam Fazeli, Head of Research, Senior Pharmaceuticals Analyst, Bloomberg Intelligence
- Sandra von Meier, Head Business Development & Licensing, Debiopharm International SA
- Sanja Tomovska, Co-Founder & CEO, Quant Biomarkers AG
- Sara Nunez-Garcia, Co-Founder & Partner, Forty51 Ventures
- Sarah Holland, President of Swiss Healthcare Licensing Group & CBO, Cureteq AG
- Seth Goldblum, SVP – Corporate Development, Cullgen Inc.
- Shelley Margetson, Managing Partner, V-Bio Ventures B
- Stephan Emmerth, Director, BaseLaunch
- Stephane Degove, CEO, Atamyo Therapeutics SAS
- Stephanie Léouzon, Managing Director & Vice Chair of European Healthcare Investment Banking, Stifel
- Steve Dickman, CEO, CBT Advisors
- Victoria English, Co-Founder & Editor, Evernow Publishing Ltd, publisher of MedNous
- Ximing Ding, Investment Manager, Pureos Bioventures